Market Place
Sourcing Support
NICE says AZ, Daiichi failed to propose fair price on Enhertu
19 Nov 2024 //
FIERCE PHARMA
Daiichi Sankyo to Showcase TURALIO® at CTOS for Giant Cell Tumor
13 Nov 2024 //
BUSINESSWIRE
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu News
09 Nov 2024 //
PHARMAPHORUM
Enhertu Wins 2024 Prix Galien USA Best Biotech Product
08 Nov 2024 //
BUSINESSWIRE
Datopotamab Deruxtecan-Based Trials Start in Advanced NSCLC
30 Oct 2024 //
BUSINESSWIRE
AZ, Daiichi promote better care for Black breast cancer patients
15 Oct 2024 //
FIERCE PHARMA
MILOS Study Highlights Bempedoic Acid`s Potential In Dyslipidemia
11 Oct 2024 //
EXPRESSPHARMA
ENHERTU® Gets Priority Review For HER2-Low Breast Cancer
01 Oct 2024 //
BUSINESSWIRE
ENHERTU Granted Priority Review For HER2 Low Breast Cancer
30 Sep 2024 //
BUSINESSWIRE
MILOS German Cohort Results Show Increase In LDL-C Goal With
27 Sep 2024 //
BUSINESSWIRE
Datopotamab Deruxtecan Results In TROPION-Breast01 Trial
23 Sep 2024 //
BUSINESSWIRE
Datopotamab Deruxtecan Final OS Results In Breast Cancer Trial
23 Sep 2024 //
BUSINESSWIRE
AstraZeneca`s drug disappoints in breast cancer survival trial
23 Sep 2024 //
REUTERS
Daiichi, AZ Launch Enhertu DTC Campaign
19 Sep 2024 //
FIERCE PHARMA
Biopharma Leaders Discuss AI Implementation In Marketing
18 Sep 2024 //
FIERCE PHARMA
Merck, Daiichi`s ADC Lung Cancer Trial Shows Promise Despite Deaths
18 Sep 2024 //
BUSINESSWIRE
DS-9606 Shows Promise In Patients With Advanced Solid Tumors
15 Sep 2024 //
BUSINESSWIRE
AZ, Daiichi build case for Enhertu in breast cancer patients with brain metastases
14 Sep 2024 //
FEIRCE PHARMA
ENHERTU Shows Activity In HER2+ Breast Cancer With Brain Metastases
13 Sep 2024 //
BUSINESSWIRE
Novel TROP2 Biomarker Predicts Outcomes In NSCLC TROPION-Lung01 Trial
09 Sep 2024 //
BUSINESSWIRE
Ifinatamab Deruxtecan Shows Promise In Small Cell Lung Cancer Trial
07 Sep 2024 //
BUSINESSWIRE
Daiichi Sankyo Unveils New ADC Research in Multiple Cancers at WCLC and ESMO
04 Sep 2024 //
BUSINESSWIRE
Daiichi study finds gender inequality in European cardiovascular care
03 Sep 2024 //
FIERCE PHARMA
Daiichi Sankyo Light on Inequalities and Unmet Needs With Cardio Disease
01 Sep 2024 //
BUSINESSWIRE
ENHERTU Gets US Breakthrough Status For HER2 Low/Ultralow Breast Cancer
19 Aug 2024 //
BUSINESSWIRE
EMA Validates ENHERTU For HER2 Low/Ultralow Metastatic Breast Cancer
19 Aug 2024 //
BUSINESSWIRE
Merck Advances Lung Cancer Strategy With Daiichi Deal And Combo Plans
06 Aug 2024 //
FIERCE BIOTECH
First Patient Dosed In IDeate-Lung02 Trial Of Ifinatamab Deruxtecan
03 Aug 2024 //
PHARMABIZ
IDeate-Lung02 Phase 3 Trial Of Ifinatamab Deruxtecan Initiated
01 Aug 2024 //
BUSINESSWIRE
Enhertu stalls as AstraZeneca, Daiichi navigate `harder yards` for ADC star
25 Jul 2024 //
FIERCE PHARMA
Daiichi Sankyo Opens New Affiliate for Oncology in Greece
10 Jul 2024 //
BUSINESSWIRE
Without Pfizer appeal, Daiichi closes long-running ADC patent with $47M win
28 Jun 2024 //
FIERCE PHARMA
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
28 Jun 2024 //
BUSINESSWIRE
US FDA declines to approve Merck-Daiichi`s `guided missile` cancer drug
28 Jun 2024 //
REUTERS
FDA rejects Merck`s first ADC in Daiichi partnership
27 Jun 2024 //
FIERCE PHARMA
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter From FDA
26 Jun 2024 //
BUSINESSWIRE
Daiichi Sankyo’s Ezharmia Receives Japanese Approval For T-Cell Lymphoma
25 Jun 2024 //
PHARMABIZ
Mika Collaborates with AstraZeneca and Daiichi for Breast Cancer Treatment
18 Jun 2024 //
GLOBENEWSWIRE
Bempedoic Acid Cut CVD Risk Across Patient Groups Per CLEAR Outcomes
29 May 2024 //
BUSINESSWIRE
RevolKa enters master service agreement with Daiichi Sankyo
29 May 2024 //
PHARMABIZ
RevolKa Signs Master Service Agreement with Daiichi Sankyo
28 May 2024 //
CONTRACT PHARMA
AstraZeneca-Daiichi`s Dato-DXd didn`t prove OS benefit in ph. 3
28 May 2024 //
FIERCE BIOTECH
Tropion-Lung01: Nsclc Vs Chemo Clinically Meaningful Improvement
27 May 2024 //
BUSINESSWIRE
Holistic Cv Care Recommendations: From European Multidisciplinary Think Tank
27 May 2024 //
BUSINESSWIRE
RevolKa Signed Master Service Agreement with Daiichi Sankyo
27 May 2024 //
BUSINESSWIRE
Japanese pharma firm Daiichi Sankyo sets up new research sites in US, Germany
23 May 2024 //
BIOSPECTRUM ASIA
NILEMDO, NUSTENDI Approved In EU For Cholesterol Lowering
22 May 2024 //
BUSINESSWIRE
Daiichi Sankyo Highlights Cancer Care Progress At ASCO
21 May 2024 //
BUSINESSWIRE
AZ, Daiichi tout Enhertu win in earlier, broader HER2-low cancer
29 Apr 2024 //
FIERCE PHARMA
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
06 Apr 2024 //
REUTERS
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy
05 Apr 2024 //
BUSINESSWIRE
Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients
03 Apr 2024 //
BUSINESSWIRE
AZ & Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for breast cancer
02 Apr 2024 //
INDIANPHARMAPOST
CHMP positive opinions for bempedoic acid and the bempedoic acid / ezetimibe
22 Mar 2024 //
BUSINESSWIRE
Two Datopotamab Deruxtecan Applications Validated in EU for Patients with NSCLC
04 Mar 2024 //
BUSINESSWIRE
Daiichi Sankyo spends €1B to bulk up in ADCs
20 Feb 2024 //
FIERCE PHARMA
Dato-DXd BLA accepted in the US for patients with advanced nonsquamous NSCLC
19 Feb 2024 //
BUSINESSWIRE
Daiichi invests 1 bln eur near Munich to make precision cancer drugs
17 Feb 2024 //
PRESS RELEASE
